Yan Shan-Shan, Campos de Souza Senio, Xie Zhen-Dong, Bao Yong-Xin
Department of Anesthesiology Southwest Medical University Luzhou China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences University of Macau Macau SAR China.
Ibrain. 2023 Mar 5;9(2):214-230. doi: 10.1002/ibra.12095. eCollection 2023 Summer.
The incidence of stroke and neurodegenerative diseases is gradually increasing in modern society, but there is still no treatment that is effective enough. Stem cells are cells that can reproduce (self-renew) and differentiate into the body, which have shown significance in basic research, while doctors have also taken them into clinical trials to determine their efficacy and safety. Existing clinical trials mainly include middle-aged and elderly patients with stroke or Parkinson's disease (mostly 40-80 years old), mainly involving injection of mesenchymal stem cells and bone marrow mesenchymal stem cells through the veins and the putamen, with a dosage of mostly 10-10 cells. The neural and motor functions of the patients were restored after stem cell therapy, and the safety was found to be good during the follow-up period of 3 months to 5 years. Here, we review all clinical trials and the latest advances in stroke, Alzheimer's disease, and Parkinson's disease, with the hope that stem cell therapy will be used in the clinic in the future to achieve effective treatment rates and benefit patients.
在现代社会中，中风和神经退行性疾病的发病率正在逐渐上升，但仍然没有足够有效的治疗方法。干细胞是能够自我复制（自我更新）并分化为身体各种细胞的细胞，在基础研究中已显示出重要意义，同时医生们也已将它们用于临床试验以确定其疗效和安全性。现有的临床试验主要包括中风或帕金森病的中老年患者（大多为40 - 80岁），主要涉及通过静脉和壳核注射间充质干细胞和骨髓间充质干细胞，剂量大多为10^6 - 10^8个细胞。干细胞治疗后患者的神经和运动功能得到恢复，并且在3个月至5年的随访期内发现安全性良好。在此，我们综述了所有关于中风、阿尔茨海默病和帕金森病的临床试验及最新进展，希望干细胞疗法未来能在临床上得到应用，以实现有效治疗率并造福患者。
